Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. High Dividend Index (AUHD20)
3/24/2026, 12:00:00 AM
Pfizer and partner Valneva announced on March 24, 2026, their intention to seek regulatory approval for their Lyme disease vaccine candidate (VLA15/PF-07307405) following positive Phase 3 trial results showing over 70% efficacy. This is estimated to have a medium impact as it addresses a significant unmet medical need.
Korean Translation
화이자와 파트너사 발네바는 2026년 3월 24일, 3상 임상시험에서 70% 이상의 효능을 보인 라임병 백신 후보물질(VLA15/PF-07307405)에 대한 규제 승인을 추진할 것이라고 발표함. 미충족 의료 수요가 높은 분야로 상당한 시장 영향이 예상됨.
Related Recent Events
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM
Antero Midstream Corp (AM) · Earnings Release
Q1 2026 earnings release, with low importance estimated due to minimal impact of date announcements, scheduled.
4/29/2026, 12:00:00 AM
Peoples Bancorp Inc (PEBO) · Earnings Release
First quarter 2026 earnings release is scheduled.
4/28/2026, 12:00:00 AM
Verizon Communications Inc (VZ) · Earnings Release
Verizon is scheduled to release its Q1 2026 earnings results on April 27, 2026, with analysts forecasting earnings of approximately $1.23 per share; low importance is estimated as market impact is typically deferred until the release scheduled.
4/27/2026, 12:00:00 AM
First Financial Bancorp. (FFBC) · Earnings Release
Benzinga and MarketBeat estimate First Financial Bancorp. will report Q1 2026 earnings on 2026-04-23, with BankFinancial integration trends likely a key focus; a mid-single-digit stock move is estimated.
4/23/2026, 12:00:00 AM
CVB Financial Corp (CVBF) · Earnings Release
First quarter 2026 earnings conference call for 2026-04-23 scheduled.
4/23/2026, 12:00:00 AM